Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: engineered toxin bodies - Bristol Myers Squibb/Molecular Templates

Drug Profile

Research programme: engineered toxin bodies - Bristol Myers Squibb/Molecular Templates

Alternative Names: ETBs - Bristol Myers Squibb/Molecular Templates

Latest Information Update: 02 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb; Molecular Templates
  • Class Antineoplastics; Bacterial toxins; Drug conjugates; Immunoglobulin fragments; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Cell death stimulants; Protein synthesis inhibitors; Proto-oncogene protein c-kit expression inhibitors; TROP2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 01 Apr 2024 Bristol-Myers Squibb plans to terminates its licence for engineered toxin body effective on June 13, 2024
  • 12 Apr 2022 Pharmacodynamics data from a preclinical studies in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
  • 11 Feb 2021 Bristol-Myers Squibb and Molecular Templates signs R&D agreement for engineered toxin body
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top